Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis

[EN] To date, anti-tumor necrosis factor alfa (anti-TNF-α) therapy is the only alternative to nonsteroidal anti-inflammatory drugs for the treatment of ankylosing spondylitis. Etanercept is a soluble TNF receptor, with a mode of action and pharmacokinetics different to those of antibodies and distin...

Descripción completa

Detalles Bibliográficos
Autores: Senabre-Gallego, José Miguel, Santos-Ramírez, Carlos, Santos-Soler, Gregorio, Salas-Heredia, Esteban, Sánchez Barrioluengo, Mabel, Barber, Xavier, Rosas, Jose
Tipo de recurso: artículo
Fecha de publicación:2013
País:España
Institución:Universitat Politècnica de València (UPV)
Repositorio:RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Idioma:inglés
OAI Identifier:oai:riunet.upv.es:10251/84332
Acceso en línea:https://riunet.upv.es/handle/10251/84332
Access Level:acceso abierto
Palabra clave:Ankylosing spondylitis
Etanercept,
Spondyloarthritis
Efficacy
Safety
ESTADISTICA E INVESTIGACION OPERATIVA
id ES_a7fd42dacb14b17d52859e75bb12facf
oai_identifier_str oai:riunet.upv.es:10251/84332
network_acronym_str ES
network_name_str España
repository_id_str
spelling Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitisSenabre-Gallego, José MiguelSantos-Ramírez, CarlosSantos-Soler, GregorioSalas-Heredia, EstebanSánchez Barrioluengo, MabelBarber, XavierRosas, JoseAnkylosing spondylitisEtanercept,SpondyloarthritisEfficacySafetyESTADISTICA E INVESTIGACION OPERATIVA[EN] To date, anti-tumor necrosis factor alfa (anti-TNF-α) therapy is the only alternative to nonsteroidal anti-inflammatory drugs for the treatment of ankylosing spondylitis. Etanercept is a soluble TNF receptor, with a mode of action and pharmacokinetics different to those of antibodies and distinctive efficacy and safety. Etanercept has demonstrated efficacy in the treatment of ankylosing spondylitis, with or without radiographic sacroiliitis, and other manifestations of the disease, including peripheral arthritis, enthesitis, and psoriasis. Etanercept is not efficacious in inflammatory bowel disease, and its efficacy in the treatment of uveitis appears to be lower than that of other anti-TNF drugs. Studies of etanercept confirmed regression of bone edema on magnetic resonance imaging of the spine and sacroiliac joint, but failed to reduce radiographic progression, as do the other anti-TNF drugs. It seems that a proportion of patients remain in disease remission when the etanercept dose is reduced or administration intervals are extended. Etanercept is generally well tolerated with an acceptable safety profile in the treatment of ankylosing spondylitis. The most common adverse effect of etanercept treatment is injection site reactions, which are generally self-limiting. Reactivation of tuberculosis, reactivation of hepatitis B virus infection, congestive heart failure, demyelinating neurologic disorders, hematologic disorders like aplastic anemia and pancytopenia, vasculitis, immunogenicity, and exacerbation or induction of psoriasis are class effects of all the anti-TNF drugs, and have been seen in patients with ankylosing spondylitis. However, etanercept is less likely to induce reactivation of tuberculosis than the other anti-TNF drugs and it has been suggested that etanercept might be less immunogenic, especially in ankylosing spondylitis. Acute uveitis, Crohn’s disease, and sarcoidosis are other adverse events that have been rarely associated with etanercept therapy in patients with ankylosing spondylitis.Dove Medical PressRepositorio Institucional de la Universitat Politècnica de València Riunet20132013-01-01journal articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://riunet.upv.es/handle/10251/84332reponame:RiuNet. Repositorio Institucional de la Universitat Politécnica de Valénciainstname:Universitat Politècnica de València (UPV)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Reconocimiento - No comercial (by-nc) http://creativecommons.org/licenses/by-nc/4.0/info:eu-repo/semantics/openAccessoai:riunet.upv.es:10251/843322026-06-13T07:49:27Z
dc.title.none.fl_str_mv Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis
title Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis
spellingShingle Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis
Senabre-Gallego, José Miguel
Ankylosing spondylitis
Etanercept,
Spondyloarthritis
Efficacy
Safety
ESTADISTICA E INVESTIGACION OPERATIVA
title_short Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis
title_full Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis
title_fullStr Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis
title_full_unstemmed Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis
title_sort Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis
dc.creator.none.fl_str_mv Senabre-Gallego, José Miguel
Santos-Ramírez, Carlos
Santos-Soler, Gregorio
Salas-Heredia, Esteban
Sánchez Barrioluengo, Mabel
Barber, Xavier
Rosas, Jose
author Senabre-Gallego, José Miguel
author_facet Senabre-Gallego, José Miguel
Santos-Ramírez, Carlos
Santos-Soler, Gregorio
Salas-Heredia, Esteban
Sánchez Barrioluengo, Mabel
Barber, Xavier
Rosas, Jose
author_role author
author2 Santos-Ramírez, Carlos
Santos-Soler, Gregorio
Salas-Heredia, Esteban
Sánchez Barrioluengo, Mabel
Barber, Xavier
Rosas, Jose
author2_role author
author
author
author
author
author
dc.contributor.none.fl_str_mv Repositorio Institucional de la Universitat Politècnica de València Riunet
dc.subject.none.fl_str_mv Ankylosing spondylitis
Etanercept,
Spondyloarthritis
Efficacy
Safety
ESTADISTICA E INVESTIGACION OPERATIVA
topic Ankylosing spondylitis
Etanercept,
Spondyloarthritis
Efficacy
Safety
ESTADISTICA E INVESTIGACION OPERATIVA
description [EN] To date, anti-tumor necrosis factor alfa (anti-TNF-α) therapy is the only alternative to nonsteroidal anti-inflammatory drugs for the treatment of ankylosing spondylitis. Etanercept is a soluble TNF receptor, with a mode of action and pharmacokinetics different to those of antibodies and distinctive efficacy and safety. Etanercept has demonstrated efficacy in the treatment of ankylosing spondylitis, with or without radiographic sacroiliitis, and other manifestations of the disease, including peripheral arthritis, enthesitis, and psoriasis. Etanercept is not efficacious in inflammatory bowel disease, and its efficacy in the treatment of uveitis appears to be lower than that of other anti-TNF drugs. Studies of etanercept confirmed regression of bone edema on magnetic resonance imaging of the spine and sacroiliac joint, but failed to reduce radiographic progression, as do the other anti-TNF drugs. It seems that a proportion of patients remain in disease remission when the etanercept dose is reduced or administration intervals are extended. Etanercept is generally well tolerated with an acceptable safety profile in the treatment of ankylosing spondylitis. The most common adverse effect of etanercept treatment is injection site reactions, which are generally self-limiting. Reactivation of tuberculosis, reactivation of hepatitis B virus infection, congestive heart failure, demyelinating neurologic disorders, hematologic disorders like aplastic anemia and pancytopenia, vasculitis, immunogenicity, and exacerbation or induction of psoriasis are class effects of all the anti-TNF drugs, and have been seen in patients with ankylosing spondylitis. However, etanercept is less likely to induce reactivation of tuberculosis than the other anti-TNF drugs and it has been suggested that etanercept might be less immunogenic, especially in ankylosing spondylitis. Acute uveitis, Crohn’s disease, and sarcoidosis are other adverse events that have been rarely associated with etanercept therapy in patients with ankylosing spondylitis.
publishDate 2013
dc.date.none.fl_str_mv 2013
2013-01-01
dc.type.none.fl_str_mv journal article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://riunet.upv.es/handle/10251/84332
url https://riunet.upv.es/handle/10251/84332
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Reconocimiento - No comercial (by-nc)
http://creativecommons.org/licenses/by-nc/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Reconocimiento - No comercial (by-nc)
http://creativecommons.org/licenses/by-nc/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Dove Medical Press
publisher.none.fl_str_mv Dove Medical Press
dc.source.none.fl_str_mv reponame:RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
instname:Universitat Politècnica de València (UPV)
instname_str Universitat Politècnica de València (UPV)
reponame_str RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
collection RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869415841808777216
score 15.301603

Similares en LA Referencia